In vivo evidence of the specificity of effects of GABAA receptor modulating medications

Sleep

Volumn 33, Issue 7, 2010, Pages 859-860

  Krystal, Andrew D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; LORAZEPAM; QUAZEPAM; TEMAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM;

ACETYLCHOLINE RELEASE; ANXIETY DISORDER; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ELECTROENCEPHALOGRAM; HUMAN; INSOMNIA; NOTE; PRIORITY JOURNAL; SEIZURE;

EID: 77954351066     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/33.7.859     Document Type: Note

References (15)

1. Tobler I, Kopp C, Deboer T, Rudolph U. Diazepam-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. Proc Natl Acad Sci U S A 2001;98:6464-9.
2. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009;13:265-74.
3. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60.
4. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008;65:551-62.
5. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol 2009;29:222-30.
6. Savić MM, Obradović DI, Ugresić ND, Cook JM, Yin W, Bokonjić DR. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav 2004;79:279-90.
7. Fradley RL, Guscott MR, Bull S, et al. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. J Psychopharmacol 2007;21:384-91. (Pubitemid 47077297)
8. Dias R, Sheppard WF, Fradley RL, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci 2005;25:10682-8. (Pubitemid 41681916)
9. Mohler H, Benke D, Mertens S, Fritschy JM. GABAA-receptor subtypes differing in alpha-subunit composition display unique pharmacological properties. Adv Biochem Psychopharmacol 1992;47:41-53.
10. Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric acid-gated Cl- currents. Mol Pharmacol 1991;39:691-6.
11. Wafford KA, Whiting PJ, Kemp JA. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol Pharmacol 1993;43:240-4.
12. Atack JR, Wafford KA, Tye SJ, et al. TPA023 [7-(1,1-dimethylethyl)-6-(2- ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 2006;316:410-22.
13. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000;3:587-92.
14. Jia F, Goldstein PA, Harrison NL. The modulation of synaptic GABA(A) receptors in the thalamus by eszopiclone and zolpidem. J Pharmacol Exp Ther 2009;328:1000-6.
15. Hambrecht-Wiedbusch VS, Gauthier EA, Baghdoyan HA, Lydic R. Benzodiazepine receptor agonists cause drug-specific and state-specific alterations in EEG power and acetylcholine release in rat pontine reticular formation. Sleep 2010;33:909-918.